Extended-Duration Betrixaban Reduces the Risk of Rehospitalization Associated With Venous Thromboembolism Among Acutely Ill Hospitalized Medical Patients: Findings From the APEX Trial (Acute Medically Ill Venous Thromboembolism Prevention With Extended Duration Betrixaban Trial)

Circulation. 2018 Jan 2;137(1):91-94. doi: 10.1161/CIRCULATIONAHA.117.031187.

¹ Cardiovascular Division, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA (G.C., M.K.Y., C.M.G.).
² Department of Medicine, University of California, Irvine (A.N.A.).
³ Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (S.Z.G.).
⁴ Duke University and Duke Clinical Research Institute, Durham, NC (A.F.H.).
⁵ Division of Cardiology, Faculty of Medicine, University of Calgary, Canada (R.D.H.).
⁶ Department of Haematological Medicine, Guy's and St. Thomas' Hospitals, King's College London, UK (A.T.C.).
⁷ Division of Cardiovascular Medicine, Department of Medicine, Stanford University, CA (R.A.H.).
⁸ Cardiovascular Division, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA (G.C., M.K.Y., C.M.G.) [email protected].

No abstract available

Keywords: anticoagulants; factor Xa inhibitors; hospitalization; venous thromboembolism; venous thrombosis.

Publication types